Choline to Improve Malnutrition and Enhance Cognition (CHIME-SAM)

The goal of this clinical trial is to test adding choline to ready-to-use therapeutic food (RUTF) in children with severe acute malnutrition (SAM) in Malawi. The main question it aims to answer is:

- Will the addition of a 500mg daily dose of choline to RUTF during treatment for SAM improve cognitive development among 6-59-month-old Malawian children compared with standard RUTF without added choline?

Study Overview

• Status: Recruiting
• Conditions: Cognitive Impairment; Wasting; Severe Acute Malnutrition; Kwashiorkor
• Intervention / Treatment: Dietary supplement: C-RUTF (Ready-to-Use Therapeutic Food with added choline); Drug: Amoxicillin; Dietary supplement: S-RUTF (Ready-to-Use Therapeutic Food without added choline)

Detailed Description

Severe acute malnutrition (SAM) affects approximately 14 million children worldwide at any one time and has an annual incidence of 3-5x this number. SAM is defined by wasting (mid-upper arm circumference < 11.5 cm or weight-for-length z-score < -3) or presence of bilateral pedal pitting edema. SAM increases short-term risks for infection, hospitalization, and death, as well as longer-term risks for stunted linear growth and impaired cognitive development. This lattermost consequence is increasingly recognized, with studies showing that children who have suffered from SAM score 2-3 standard deviations below age-expected norms on cognitive development tests.

Ready-to-use therapeutic food (RUTF) revolutionized SAM treatment by allowing it to occur in the home setting. RUTF cures most children with SAM and ameliorates many of its worst consequences. RUTF was designed to be food-safe and promote anthropometric recovery. Since its inception, evidence has accumulated suggesting that the original fatty acid content of RUTF was not optimized for cognitive recovery from SAM. A 2021 trial, the Improved PUFA Trial (PMID: 34726694), demonstrated that reducing the omega-6 fatty acid content of RUTF and adding docosahexaenoic acid (DHA) improved cognitive development 6 months after SAM treatment in Malawian children. It is possible that further modifications to RUTF's composition might promote greater cognitive recovery.

Choline is essential for human health and development and is recognized as such by the Institute of Medicine, which designates daily recommended intakes. Choline deficiency has been shown to induce a host of cognitive developmental problems in animal models, is associated with neural tube defects in humans, and mutations of choline transporters in humans yield developmental degenerative conditions which, while rare, shed light on the essential nature of choline in brain development. Several small randomized, controlled trials have shown benefits of choline supplementation during early life on child cognitive development, both in healthy children and in those exposed to insults such as in fetal alcohol syndrome.

Choline plays important roles in brain structure and function and is found primarily in animal-source foods, which are deficient in the diets of children with SAM. Choline is an essential component of the neuronal membrane as well as a precursor for acetylcholine, a key neurotransmitter. In addition, choline plays a role in the trafficking and cell membrane integration of DHA, which rapidly accumulates in the human brain during childhood and ultimately composes 40-50% of brain polyunsaturated fatty acids. Decades of findings from epidemiological studies and laboratory science, including with animal models, support the essential role of DHA in the structure and function of the brain and retina. The Improved PUFA Trial leveraged these insights and showed that the developing brain is sensitive to fatty acid intake in the context of SAM; providing DHA in RUTF improved brain development. Hepatic export of DHA into plasma and its target tissues, including the brain, relies in part on synthesis of phosphatidylcholine (PC) by phosphatidylethanolamine N-methyltransferase (PEMT). DHA-enriched PC molecules (PC-DHA) are generated by PEMT and exported for delivery throughout the body. Indeed, PEMT-deficient mice have reduced DHA plasma concentrations and pups born to PEMT-deficient dams have limited DHA brain accumulation. The PEMT pathway relies on adequate supply of dietary methyl donors such as choline. Pairing (1) choline's ability to increase DHA trafficking to/integration within the brain with (2) the power of DHA in SAM, it is possible that adding choline to RUTF containing DHA might promote cognitive recovery and development among malnourished children.

This will be an individually randomized, investigator/outcomes assessors/caregiver-blinded, controlled clinical trial designed to determine whether the addition of a daily dose of 500mg of choline to ready-to-use therapeutic food (C-RUTF) will improve cognitive development among Malawian children 6-59 months of age with SAM compared with standard RUTF (S-RUTF). This trial will be conducted at 10 rural sites in southern Malawi. 1500 children will be randomized 1:1 to receive 2 sachets per day of either C-RUTF or S-RUTF. Children will receive their allocated RUTF and return to clinic fortnightly for repeat anthropometric measurements, illness questions, and to receive more RUTF until they achieve a clinical outcome or for a maximum of 12 weeks, at which point they will undergo Malawi Developmental Assessment Tool (MDAT) testing and blood spot collection. Participants will be asked to return to clinic 5-7 months later for MDAT testing, the global z-score from which will be the trial's primary outcome.

• Study Type: Interventional
• Enrollment (Estimated): 1500
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Mark J Manary, MD; Phone Number: +1 314-454-2341; Email: manarymj@wustl.edu

Study Locations

• Malawi
  • Chikwawa
    • Makhwira, Chikwawa, Malawi
      • Recruiting
      • Makhwira
      • Contact: Lameck Kachali
    • Mitondo, Chikwawa, Malawi
      • Recruiting
      • Mitondo
      • Contact: Lameck Kachali
    • Nkhate, Chikwawa, Malawi
      • Recruiting
      • Nkhate
      • Contact: Lameck Kachali
  • Machinga
    • Chipolonga, Machinga, Malawi
      • Recruiting
      • Chipolonga
      • Contact: Lameck Kachali
  • Mulanje
    • Chikonde, Mulanje, Malawi
      • Recruiting
      • Chikonde
      • Contact: Lameck Kachali
    • Mbiza, Mulanje, Malawi
      • Recruiting
      • Mbiza
      • Contact: Lameck Kachali
    • Milonde, Mulanje, Malawi
      • Recruiting
      • Milonde
      • Contact: Lameck Kachali
    • Muloza, Mulanje, Malawi
      • Recruiting
      • Muloza
      • Contact: Lameck Kachali
    • Namasalima, Mulanje, Malawi
      • Recruiting
      • Namasalima
      • Contact: Lameck Kachali
    • Naphimba, Mulanje, Malawi
      • Recruiting
      • Naphimba
      • Contact: Lameck Kachali

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 6-59 months of age
• mid-upper arm circumference < 11.5 cm and/or weight-for-length z-score < -3 and/or presence of bilateral pedal pitting edema
• willingness to comply with all study procedures and availability for the duration of the study, including no plan to move from the catchment area of a participating clinic

Exclusion Criteria:

• features of complicated SAM: inability to tolerate a 30g test dose of RUTF, breathing difficulties, mental status changes, sepsis, or physician/nursing clinical assessment that the child needs immediate hospitalization
• participation in a separate feeding program within the past month
• known allergy to study food ingredient (peanut, milk, fish)
• intention to move away from catchment area within 9 months
• developmental delay
• presence of a chronic severe medical condition (other than TB and HIV), such as congenital heart disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: C-RUTF (Ready-to-Use Therapeutic Food with added choline); A daily dose of 500mg choline will be added to RUTF. 2 sachets (daily dose) of RUTF will provide approximately 1000 Kcal, 14g of protein, 28g of fat, and 1 RDA of 14 micronutrients.	Dietary supplement: C-RUTF (Ready-to-Use Therapeutic Food with added choline); Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications; Drug: Amoxicillin; Oral amoxicillin tablets twice per day for 7 days dosed based on weight
Active Comparator: S-RUTF (Ready-to-Use Therapeutic Food without added choline); A daily dose of 5mg choline will be added to RUTF for masking. 2 sachets (daily dose) of RUTF will provide approximately 1000 Kcal, 14g of protein, 28g of fat, and 1 RDA or 14 micronutrients.	Drug: Amoxicillin; Oral amoxicillin tablets twice per day for 7 days dosed based on weight; Dietary supplement: S-RUTF (Ready-to-Use Therapeutic Food without added choline); Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Malawi Developmental Assessment Tool global z-score	Age-standardized score, -6 to +6, higher scores are better	6 months after SAM outcome

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Malawi Developmental Assessment Tool gross motor sub-domain z-score	Age-standardized score, -6 to +6, higher scores are better	6 months after SAM outcome
Malawi Developmental Assessment Tool fine motor sub-domain z-score	Age-standardized score, -6 to +6, higher scores are better	6 months after SAM outcome
Malawi Developmental Assessment Tool language sub-domain z-score	Age-standardized score, -6 to +6, higher scores are better	6 months after SAM outcome
Malawi Developmental Assessment Tool social sub-domain z-score	Age-standardized score, -6 to +6, higher scores are better	6 months after SAM outcome
Malawi Developmental Assessment Tool global z-score	Age-standardized score, -6 to +6, higher scores are better	Within 1 month of SAM outcome
Malawi Developmental Assessment Tool gross motor sub-domain z-score	Age-standardized score, -6 to +6, higher scores are better	Within 1 month of SAM outcome
Malawi Developmental Assessment Tool fine motor sub-domain z-score	Age-standardized score, -6 to +6, higher scores are better	Within 1 month of SAM outcome
Malawi Developmental Assessment Tool language sub-domain z-score	Age-standardized score, -6 to +6, higher scores are better	Within 1 month of SAM outcome
Malawi Developmental Assessment Tool social sub-domain z-score	Age-standardized score, -6 to +6, higher scores are better	Within 1 month of SAM outcome
Recovery	Defined based on enrollment (anthropometric +/- edema) criteria	2-12 weeks of therapeutic feeding
DHA status	Blood spot DHA % of total fatty acids in subset of participants	2-12 weeks of therapeutic feeding (until SAM outcome)
Time-to-kwashiorkor resolution	Time to resolution of nutritional edema	2-12 weeks of therapeutic feeding
Rate of weight gain	g/kg/day	2-12 weeks of therapeutic feeding (until SAM outcome)
Rate of length gain	mm/week	2-12 weeks of therapeutic feeding (until SAM outcome)
Diarrhea	Days, reported by caregiver, safety outcome	2-12 weeks of therapeutic feeding (until SAM outcome)
Time-to-recovery	Weeks until recovery criteria met, with recovery defined based on enrollment criteria	2-12 weeks of therapeutic feeding
Proportion of participants who die	Defined by caregiver report	2-12 weeks of therapeutic feeding
Proportion of participants who die	Defined by caregiver report	From enrollment to study end (6-month post-SAM-outcome MDAT visit)
Proportion of participants remaining with SAM	Continue to meet SAM criteria after feeding	After 12 weeks of therapeutic feeding
Proportion of participants with kwashiorkor resolution	Resolution of nutritional edema	2-12 weeks of therapeutic feeding
Proportion of participants with recurrence of SAM	After recovery, again meeting criteria for SAM	From recovery until study end (6-month post-SAM-outcome MDAT visit)
Change in MDAT global z-score	Difference in MDAT global z-score between 6-month post-SAM outcome visit and MDAT, global z-score measured within 1 month of SAM outcome, more positive scores are better	From MDAT near time of SAM outcome to 6-month post-SAM-outcome MDAT visit
Proportion of participations requiring hospitalization	Safety outcome	Enrollment to 6-month post-SAM-outcome MDAT visit)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
MDAT global z-score by age	Subgroups: enrollment <12 vs. >=12 months of age, -6 to +6, higher scores are better	6-month post-outcome MDAT visit
MDAT global z-score by SAM outcome status	Subgroups: Recovered vs. Other, -6 to +6, higher scores are better	6-month post-outcome MDAT visit

Collaborators and Investigators

• Sponsor: Washington University School of Medicine
• Collaborators: Kamuzu University of Health Sciences; Project Peanut Butter; Balchem Corporation
• Investigators: Principal Investigator: Mark J Manary, MD, Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): December 5, 2023
• Primary Completion (Estimated): March 1, 2026
• Study Completion (Estimated): March 1, 2026

Study Registration Dates

• First Submitted: October 18, 2023
• First Submitted That Met QC Criteria: November 28, 2023
• First Posted (Actual): December 4, 2023

Study Record Updates

• Last Update Posted (Actual): December 20, 2023
• Last Update Submitted That Met QC Criteria: December 19, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Malnutrition; Severe Acute Malnutrition; Kwashiorkor; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antimetabolites; Gastrointestinal Agents; Hypolipidemic Agents; Lipid Regulating Agents; Anti-Bacterial Agents; Nootropic Agents; Lipotropic Agents; Amoxicillin; Choline
• Other Study ID Numbers: 202308160

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All collected, de-identified individual patient data
• IPD Sharing Time Frame: Within 12 months of primary publication
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No